SpaceX Stock Is Down 23% From Its Post-IPO High. History Says This Will Happen Next. (Hint: It's a Big Move.)

SpaceX has fallen 23% from its post-IPO high of $202 to $156, and the article argues history suggests further downside: among the 15 largest IPOs since 2006, the average stock later dropped 50% from its IPO price during the first year and finished the year 33% below the IPO price. The stock trades at 104x sales versus Palantir at 55x, while analysts still see $238.50 per share, implying 53% upside from current levels. Overall, the piece is a cautionary valuation and post-IPO performance warning rather than a fundamental catalyst.

Analysis

The key market implication is not that one high-profile listing is expensive, but that liquidity in the private-markets complex may be peaking just as a large cohort of late-stage holders finally gets a public mark. That tends to create a reflexive loop: employee/VC distributions, secondary sales, and cross-fund de-risking often intensify after the first post-IPO fade, which can pressure the entire “private-tech multiple” stack rather than just the single name. The more important second-order effect is on comparable transactions in venture and crossover portfolios, where a reset in one trophy asset can tighten underwriting for adjacent late-stage rounds.

The setup is most bearish for the highest-duration, most crowded growth proxies in the data set: PLTR, HOOD, COIN, PATH, and RIVN are the names most vulnerable to a renewed “valuation discipline” regime because they already trade on narrative rather than near-term cash-flow conversion. If the IPO weakens further over the next 4-12 weeks, expect analysts to become more conservative on revenue-multiple assumptions across the group, which could compress multiples even without estimate cuts. By contrast, NVDA and NFLX look relatively insulated here because their valuation support comes from demonstrated earnings power rather than a pure scarcity premium.

Catalyst-wise, the main risk to the bearish thesis is not fundamentals improving overnight; it is technical stabilization after early insider lockup dynamics or a broader risk-on tape that forces underweight managers to chase performance. But history suggests the first major leg lower often happens in the first 1-3 months, before the market has time to establish a durable floor. If the stock fails to hold recent lows, the next drawdown can be mechanical as late entrants and momentum buyers become forced sellers.

The contrarian angle is that the market may already be pricing in a severe de-rating, so the better expression is not outright shorting the headline name but fading its spillover beneficiaries. If the IPO multiple compresses sharply, the most crowded long-only growth baskets should underperform while profitable megacaps with clear AI/consumer monetization should absorb incremental capital. That argues for relative-value, not directional, exposure.

Key Decisions for Investors

• Short the highest-duration growth basket versus megacap quality: long NVDA / short PLTR or HOOD over the next 4-8 weeks. Risk/reward favors the long leg if the market rotates away from speculative multiple expansion.
• Pair trade: long NFLX / short RIVN or PATH into any bounce in IPO-linked sentiment. NFLX has stronger cash-flow visibility and should outperform if investors start demanding earnings support.
• For event-driven accounts, buy short-dated puts on the new issue only on rallies back toward prior highs; use a 1-2 month horizon and keep premium risk-defined. The trade is best as a volatility expression, not a hero short.
• Reduce exposure to late-stage private-market proxies in crossover and venture-linked books, especially COIN and HOOD, for the next 1-3 months. These names are most sensitive to a broader reset in growth multiples and liquidity expectations.
• If you want contrarian long exposure, wait for a 20-30% additional drawdown before initiating a starter position in the IPO itself. The historical edge is in waiting for forced liquidation, not buying the first pullback.